# Triumvira Immunologics, Inc.

> Triumvira Immunologics is a clinical-stage immuno-oncology company developing engineered T cell therapies built on its proprietary T cell Antigen Coupler (TAC) platform. Unlike CAR-T, the TAC molecule co-opts the natural T cell receptor to recognize and attack cancer cells, aiming for a more physiological immune response with a potentially safer profile. The company advances autologous and allogeneic TAC T cell candidates against solid-tumor antigens such as HER2, Claudin 18.2, GPC3 and GUCY2C.

- **Founded:** 2015
- **Headquarters:** Austin, Texas, United States
- **Founders:** Jonathan Bramson (Scientific Co-Founder (McMaster University)), Bloom Burton & Co. (Founding Investor / Co-Founder)
- **Team size:** ~24-50 employees
- **Products:** TAC (T cell Antigen Coupler) Platform, TAC01-HER2, TAC01-CLDN18.2, Preclinical pipeline
- **Notable:** Raised approximately $100M across its Series A and extension, led by Leaps by Bayer and Northpond Ventures., Granted a U.S. patent for the T cell Antigen Coupler (TAC) technology in 2019., Advanced two TAC candidates (TAC01-HER2 and TAC01-CLDN18.2) into first-in-human Phase I/II trials.

## Products & services

- **TAC (T cell Antigen Coupler) Platform** — A proprietary multi-domain chimeric molecule that engages the natural T cell receptor so a T cell can recognize and attack cancer cells, aiming for a normal immune synapse and reduced tonic signaling compared with CAR-T and engineered TCR therapies.
- **TAC01-HER2** — Autologous TAC T cell therapy targeting HER2-positive solid tumors, evaluated in the Phase I/II TACTIC-2 trial (NCT04727151).
- **TAC01-CLDN18.2** — Autologous TAC T cell therapy targeting Claudin 18.2-positive solid tumors, evaluated in the first-in-human Phase 1/2 TACTIC-3 trial (NCT05862324).
- **Preclinical pipeline** — Additional TAC programs against tumor-associated antigens including GPC3 and GUCY2C, spanning autologous and allogeneic approaches.

## Achievements

- Raised approximately $100M across its Series A and extension, led by Leaps by Bayer and Northpond Ventures.
- Granted a U.S. patent for the T cell Antigen Coupler (TAC) technology in 2019.
- Advanced two TAC candidates (TAC01-HER2 and TAC01-CLDN18.2) into first-in-human Phase I/II trials.
- Reported early TACTIC-2 data with an 86% disease control rate and 29% overall response rate across dose levels 2-4 in heavily pretreated GEJ cancer.
- Established a clinical combination collaboration with Merck pairing TAC01-HER2 with KEYTRUDA.
- Published peer-reviewed data on the safety and efficacy of TAC T cells targeting Claudin 18.2 in solid tumors.

## Latest updates

- **2024-10** — Announced publication demonstrating the safety and efficacy of TAC T cells targeting Claudin 18.2 in solid tumors.
- **2024-01** — Presented clinical data at the 2024 ASCO Gastrointestinal Cancers Symposium.
- **2023-06** — Presented TACTIC-2 clinical data for TAC01-HER2 at the 2023 ASCO Annual Meeting and ESMO World Congress on GI Cancer.
- **2023-05** — Began the first-in-human Phase 1/2 TACTIC-3 trial of TAC01-CLDN18.2 (NCT05862324).
- **2022-11** — Announced updated data from the ongoing TACTIC-2 trial of TAC01-HER2.
- **2022-03** — Closed Series A extension bringing the total round to approximately $100 million.

## Links

- Website: https://triumvira.com
- LinkedIn: https://www.linkedin.com/company/triumvira-immunologics-inc
- Twitter/X: https://twitter.com/Triumvirainc

---

Profile page: https://yespress.io/triumvira-immunologics-inc
Published by YesPress — https://yespress.io
Last updated: 2026-07-17